ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

イソカルボキサジド

Isocarboxazid

HCID 3759
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
59-63-2
標準SMILES
Cc1cc(C(=O)NNCc2ccccc2)no1
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
分子式
C12H13N3O2
平均分子量
231.25 g/mol
単同位体質量
231.10077667

概要

5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide is a member of benzenes.

名称と識別子

優先名称
Isocarboxazid
IUPAC
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
現地名
イソカルボキサジド
英語名
ISOCARBOXAZID (200 MG)
分子式
C12H13N3O2
分子量
231.25

名称と別名

isocarboxazid59-63-2IsocarboxazideEnerzerMarplanIsocarbonazidIsocarbossazideN'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazideIsocarboxazidaRo 5-0831Isocarboxazidum5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide
名称をさらに表示
マープランN'-ベンジル-5-メチル-3-イソオキサゾールカルボヒドラジドイソカルボキサジドマープロンベナジドイソカルボキシジドエナーザー1-ベンジル-2-[(5-メチルイソオキサゾール-3-イル)カルボニル]ヒドラジン5-メチル-3-イソオキサゾールカルボン酸2-ベンジルヒドラジドエネルゼルN'-ベンジル-5-メチルイソオキサゾール-3-カルボヒドラジドマルプランマルプロンN′-ベンジル-5-メチル-3-イソオキサゾールカルボヒドラジドN'-ベンジル-5-メチル-1,2-オキサゾール-3-カルボヒドラジドN′-ベンジル-5-メチルイソオキサゾール-3-カルボヒドラジド1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazineBmihMarplonBenazideMaraplanro5-0831
3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazideDTXSID4023171NSC-169893RO-5-0831NSC169893DTXCID00317134237V843T4-27-00-03999 (Beilstein Handbook Reference)

データベース識別子

CAS
59-63-2
PubChem CID
3759
DTXSID
DTXSID4023171
ChEMBL
CHEMBL1201168
ChEBI
CHEBI:93635
UNII
34237V843T
EC Number
200-438-4
Nikkaji
J4.794E

物性

構造計算による物性補完中

XLogP
1.5
極性表面積
67.2 Ų
水素結合供与体数
2
水素結合受容体数
4
回転可能結合数
4
重原子数
17
形式電荷
0
複雑度
254

実験および物理化学的性質

Drugs · 2 件

DEA NFLIS-Drug Category -> Stimulants

Pharmaceuticals -> Listed in ZINC15

LogP · 2 件

2.4

1.49

Solubility · 2 件

Very slightly soluble in hot water

2.24e-01 g/L

Human Drugs · 5 件

Antidepressants -> Monoamine oxidase inhibitors (MAOI)

Breast Feeding; Lactation; Antidepressive Agents; Monoamine Oxidase Inhibitors;

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling Point394.5ºC at 760 mmHg
Melting Point · 2 件

105-106 °C

105 - 106 °C

Physical DescriptionSolid
Dissociation Constants10.4
Collision Cross Section · 2 件

150.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Antidepressants]

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory Information3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 3 (100%)

毒性情報

Treatment · 1 件

General supportive measures should be used, along with immediate gastric lavage or emetics. If the latter are given, the danger of aspiration must be borne in mind. An adequate airway should be maintained, with supplemental oxygen if necessary. The mechanism by which amine-oxidase inhibitors produce hypotension is not fully understood, but there is evidence that these agents block the vascular bed response. Thus it is suggested that plasma may be of value in the management of this hypotension. Administration of pressor amines such as levarterenol bitartrate may be of limited value (note that their effects may be potentiated by Isocarboxazid). Continue treatment for several days until homeostasis is restored. Liver function studies are recommended during the 4 to 6 weeks after recovery, as well as the time of overdosage.

Hepatotoxicity · 1 件

Isocarboxazid, like most monoamine oxidase (MAO) inhibitors, can cause transient serum aminotransferase elevations in a proportion of patients. These elevations are usually mild, asymptomatic and self-limited and do not require dose modification. MAO inhibitors have been associated with rare cases of acute, clinically apparent liver injury but isocarboxazid has not specifically been implicated. The time to clinical onset of liver injury due to MAO inhibitors is typically 1 to 4 months after starting and the usual pattern of serum enzyme elevations is hepatocellular, although cholestatic injury has also been described. Immunoallergic features (rash, fever, eosinophilia) are uncommon as is autoantibody formation. Isocarboxazid has not been directly implicated in cases of drug-induced liver injury but it has had limited clinical use.

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein Binding · 1 件

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs present a very high protein binding percentage.

Pharmacodynamics · 1 件

In vivo and in vitro studies demonstrated isocarboxazid-driven inhibition of MAO in the brain, heart, and liver. The reduced MAO activity, caused by isocarboxazid, results in an increased concentration of serotonin, epinephrine, norepinephrine, and dopamine in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. The increase of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors like isocarboxazid.

Mechanism of Action · 1 件

Isocarboxazid works by irreversibly blocking the action of monoamine oxidases (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). Isocarboxacid, like other monoamine oxidase inhibitors, are unique psychopharmacological agents whose clinical effect is related to the direct action of the monoamine oxidases to transform them into reactive metabolites.

Biological Half-Life · 1 件

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor. These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.

Metabolism/Metabolites · 2 件

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are rapidly metabolized by acetylation in the liver. As part of the metabolism, hippuric acid is a major metabolite.

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

152.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

融点
98 · 98-1000C
沸点
373.33 °C · 373.33°C (rough estimate)
比重(密度)
1.206 · 1.206
屈折率
1.529 · 1.5290 (estimate)
貯蔵温度
-20 °C · -20°C Freezer
溶解性
Acetonitrile: Slightly Soluble; Chloroform: Slightly Soluble
外見
A solid
酸解離定数(Pka)
10.4 · pKa 10.4 (Uncertain)
色
White to off-white
水溶解度
0.8 g/L · 0.8g/L(25℃)
InChI
1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
SMILES
Cc1cc(no1)C(=O)NNCc2ccccc2

化学的性質

化学的特性Pale Yellow Solid

Exposure RoutesWell absorbed from the gastrointestinal tract.
Toxicity Summary · 1 件

Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.

Signs and Symptoms · 1 件

Signs of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Isocarboxazid

Ambiguous-DILI-concern

5

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
WGK 3
ridadr
3249
hs_code
2934990002
hazard_class
6.1(b)
packing_group
III
Hazard Classifications
Acute Tox. 3 Oral
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

Hepatic and rapid (by oxidation).

FDA Pharmacological Classification · 6 件

34237V843T

ISOCARBOXAZID

Established Pharmacologic Class [EPC] - Monoamine Oxidase Inhibitor

Mechanisms of Action [MoA] - Monoamine Oxidase Inhibitors

Isocarboxazid is a Monoamine Oxidase Inhibitor. The mechanism of action of isocarboxazid is as a Monoamine Oxidase Inhibitor.

ISOCARBOXAZID

MeSH Pharmacological Classification · 2 件

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)

Absorption, Distribution and Excretion · 2 件

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are readily absorbed by the GI tract, present a low bioavailability and reach peak concentrations in 1-2 hours.

Most of the eliminated dose is found in the urine, accounting for the 42.5% of the administered dose after 24 hours. From this amount, 75% of the renally eliminated drug is in the form of hippuric acid. Another section of the eliminated dose is observed through the intestinal tract and it accounts for 22% of the administered dose after 24 hours.

Cellular LocationsCytoplasm

用途と製造

UsesMay be used to treat major depressive disorder.
Use ClassificationPharmaceuticals

応用分野

使用Monoamine oxidase inhibitor. Antidepressant

上流・下流製品情報

上流原料

水素化リチウムアルミニウムベンズアルデヒド5-メチルイソオキサゾール-3-カルボヒドラジドベンジルヒドラジン二塩酸塩5-メチル-3-イソオキサゾールカルボン酸ベンジリデンヒドラジド5-メチルイソオキサゾール-3-カルボン酸メチルベンジルヒドラジン